Description
Salmon calcitonin acetate (SCA) is clinically used to treat osteoporosis in postmenopausal women. SCA exhibits anti-osteoporotic, anti-resorptive, anti-diabetic, and chondroprotective activities. In obese animal models, SCA decreases body weight, decreases levels of plasma insulin and leptin, and improves fasting glycemia, preventing insulin resistance. In cartilage explants, SCA increases cAMP release and inhibits cartilage turnover and hypertrophy. In other animal models, SCA decreases collagen type II degradation, subchondral bone damage, and cartilage loss.
References
Feigh M, Andreassen KV, Hjuler ST, et al. Oral salmon calcitonin protects against impaired fasting glycemia, glucose intolerance, and obesity induced by high-fat diet and ovariectomy in rats. Menopause. 2013 Jul;20(7):785-94. PMID: 23793169.
Chen-An P, Andreassen KV, Henriksen K, et al. The inhibitory effect of salmon calcitonin on tri-iodothyronine induction of early hypertrophy in articular cartilage. PLoS One. 2012;7(6):e40081. PMID: 22768225.
Nielsen RH, Bay-Jensen AC, Byrjalsen I, et al. Oral salmon calcitonin reduces cartilage and bone pathology in an osteoarthritis rat model with increased subchondral bone turnover. Osteoarthritis Cartilage. 2011 Apr;19(4):466-73. PMID: 21251986.
